AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00577070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
Study NCT00577070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
Study NCT01375413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: Physical therapy consisting of gait training 3 times a week for 6 weeks
Study NCT01375413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Physical therapy consisting of gait training 3 times a week for 6 weeks
Study NCT00910377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling sessions
Description: The intervention groups received counseling sessions about breastfeeding and complementary feeding at maternity ward and at home with 7,15,30,60 and 120 days.
Study NCT01344694 — intervention group
Intervention type: OTHER
Intervention: patient with liver fat
Description: 30 patient with liver fat
Study NCT01344694 — intervention group
Intervention type: OTHER
Intervention: pts. with excess of visceral fat
Description: pts. with excess of visceral fat
Study NCT01344694 — intervention group
Intervention type: OTHER
Intervention: control
Description: 30 control subjects
Study NCT02417558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alterniity Augmented Reality (AAR)
Description: AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
Study NCT02417558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VideoGrade
Description: Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
Study NCT03282422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based protocol in specific tasks
Description: The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
Study NCT03282422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based protocol in specific tasks
Description: The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
Study NCT03282422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper-limb splint
Description: In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
Study NCT03644420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical evaluation
Description: Functional scores for the pathological joint will be determined
Study NCT03644420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiology
Study NCT04144712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate
Description: study rate of occurrence of Apnea of Prematurity between the 2 groups
Study NCT04144712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate
Description: study rate of occurrence of Apnea of Prematurity between the 2 groups
Study NCT02808975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections administered as described in arm description
Study NCT02808975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous injections administered as described in arm description
Study NCT00132678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal Consta
Description: 12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
Study NCT00132678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo intramuscular (IM) injection every 2 weeks
Study NCT03318029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation
Description: Vitamin D supplementation of 600 IU daily for 12 weeks
Study NCT03318029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: rice flour with no vitamin D
Study NCT01081847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptides (N,R&C) formulated in Montanide ISA 720
Description: 50 ug
Study NCT01081847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptides (N,R&C) formulated in Montanide ISA 51
Description: 50 ug
Study NCT01081847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptides (N,R&C) formulated in Montanide ISA 720
Description: 100 ug
Study NCT01081847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptides (N,R&C) formulated in Montanide ISA 51
Description: 100 ug
Study NCT03644420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic contrast-enhanced magnetic resonance imaging
Description: Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.
Study NCT03644420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of histological status
Description: Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
Study NCT03403452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
Study NCT01081847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLacebo: Isotonic saline solution
Study NCT00463814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Participants will receive single oral dose of AZD6244 as described in arm description.
Study NCT05691777 — intervention group
Intervention type: DEVICE
Intervention: Hand and shoulder task
Description: Hand task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform flexion / extension movements of the fingers of the right hand at 0.5 Hz.~Shoulder task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform alternating movement of abduction and adduction of the right shoulder at 0.5 Hz with the elbow flexed.
Study NCT03206840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control, meditation, hypnosis.
Description: three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects.
Study NCT01054222 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
Study NCT01054222 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
Study NCT04194047 — intervention group
Intervention type: OTHER
Intervention: Transfusion
Description: RBC transfusion (1 unit)
Study NCT04194047 — intervention group
Intervention type: OTHER
Intervention: Crystalloids infusion
Description: Infusion of 500 ml of balanced crystalloids
Study NCT04023214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral (digital) arterial tonometry
Description: This will be measured using the EndoPAT system (Itamar Medical)
Study NCT00696319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol with perturbation exercises.
Description: Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
Study NCT00696319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol with traditional exercises for stability and balance.
Description: The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
Study NCT00193739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NACT
Description: 3 cycles of neoadjuvant chemotherapy
Study NCT00193739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling
Description: NACT followed by surgery
Study NCT00193739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj.Cisplatin
Description: Concurrent chemo radiotherapy
Study NCT00193739 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemo radiotherapy
Description: Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
Study NCT04168320 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)
Description: Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
Study NCT03768336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist control
Description: The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. Waitlist control receives the adapted 3RP program (3RP-AYA) approximately 2 months after study enrollment.
Study NCT03768336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3RP-AYA
Description: The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.
Study NCT04168320 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)
Description: Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
Study NCT02865629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
Study NCT01605825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/dalfampridine-ER
Description: Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
Study NCT01605825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalfampridine-ER/placebo
Description: Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
Study NCT04053439 — intervention group
Intervention type: OTHER
Intervention: Blood test for determination of CHIP
Description: Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.
Study NCT03659162 — intervention group
Intervention type: DRUG
Intervention: Azole Antifungal
Description: oral gel \& injections
Study NCT03743779 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mastering Diabetes
Description: The Mastering Diabetes provides a step-by-step program to transition to a low-fat, plant-based, whole-food lifestyle and reduce overwhelm. The program also provides direct access to expert coaches in the online community, which contains others living with all forms of diabetes. I includes access to live Q\&A videoconferences twice per month to interact with coaches and personalize the experience.~The program is designed with seven core modules. Many participants continue in the program after completion of the modules for ongoing support.~The cost was $29/month or $249/year, but as of July 2018, only the $249/year option is offered.
Study NCT02571088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Program
Description: Each training session will last 45 min. Exercise will start by a 5-min warm-up cycling period, followed by 30 min of cycling at the power output (W) individually determined before and corresponding to the first lactate threshold corresponding approximately to 2.5 mmol/l . Then patients will cool down for 5 min. Finally, the training sessions will end by 5 min of light stretching. All training sessions will take place at the hospital and will be under the supervision of a physician. Heart rate, oxygen saturation and blood lactate concentrations will be regularly measured. Work rate will be adjusted according to the obtained results. As a safety procedure, blood lactate concentration must not exceed 4 mmol/L during the training sessions. A particular attention will be paid to the hydration of patients. Pain and fatigue will be evaluated everyday by the patients using (100 mm) visual analog scales.
Study NCT02980042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells
Study NCT02980042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: A chimeric monoclonal antibody against CD20.
Study NCT03798275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coffee
Description: 2 g Nescafe Clasico contains approximately 65 mg caffeine
Study NCT01135654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment
Description: We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much.
Study NCT01135654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment
Description: We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much.
Study NCT03289559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GnRH antagonist
Study NCT03289559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Study NCT03289559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aromatase Inhibitors
Study NCT03289559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors
Study NCT03289559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Study NCT03591484 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Treatment with Photodynamic therapy. The evaluation of halitosis and the microbiological analysis will be repeated before this step
Study NCT03591484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with tongue scraper
Description: Treatment with tongue scraper. The evaluation of halitosis and the microbiological analysis will be repeated before this step
Study NCT03591484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step
Study NCT03591484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal treatment
Description: Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step
Study NCT03591484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hygiene procedures for the mucosa and dentures
Description: edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step
Study NCT03591484 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hygiene procedures for the mucosa and dentures
Description: edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step
Study NCT01400360 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Combination of TBA and intraarterial application of vasodilators
Description: In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
Study NCT01400360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination of TBA and intraarterial application of vasodilators
Description: In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
Study NCT03546153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Description: Exercise program consists of training for 60 minutes, three times per week for 12 weeks. Participants will use a treadmill, Nu stepper/bike or elliptical to exercise.
Study NCT00664963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of YUKON Sirolimus-eluting Stent
Description: Implantation of YUKON Sirolimus-eluting Stent
Study NCT00664963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of YUKON Stent (uncoated)
Description: Implantation of YUKON Stent (uncoated)
Study NCT00790400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
Study NCT00790400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus Placebo
Description: Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
Study NCT03149575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083, Dianhydrogalactitol
Description: VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
Study NCT03149575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice of Salvage Therapy - temozolomide
Description: The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle.